UPDATE: Summer Street Research Partners Initiates Buy, $15 PT on Anthera Pharmaceuticals

Summer Street Research Partners initiates a Buy rating and a $15 target price on Anthera Pharmaceuticals

on its robust product pipeline. Summer Street Research Partners says, "ANTH is a biopharmaceutical company with two products in late-stage development to treat inflammation-related diseases: varespladib for acute coronary syndrome (

) and blisibimod for systemic lupus erythematosus. The two products combined have a potential market of $3B." ANTH closed at $6.46 a share yesterday.